Press Release

ZEISS Vision Care Completes Acquisition of Brighten Optix

Both companies will join their forces to tackle the global burden of myopia
4 December 2025

Aalen, Germany | 04 December 2025 | ZEISS Vision Care

 

Carl Zeiss Vision International GmbH announced today the closing of the acquisition of 100% of Brighten Optix, a leading player in the field of orthokeratology and specialty contact lenses. The company is known as a successful partner for optical retail, ophthalmologists, eye clinics and hospitals, especially for myopia management. This strategic move, first announced in June 2025, marks a significant step forward in ZEISS' commitment to protect and improve the vision and lifetime visual health of the world’s consumers.

Myopia, or nearsightedness, especially in its progressive form, is a growing concern worldwide, with increasing prevalence among children and adolescents. The acquisition of Brighten Optix aligns with ZEISS' ambition to expand its portfolio of advanced optical technologies and services with a focus on leading solutions for myopia management. By integrating Brighten Optix' expertise and innovative products, ZEISS will deliver even greater value to its customers and consumers, especially to children for protecting their most precious gift: their sight.

"We are excited to officially welcome Brighten Optix and their talented teams to the ZEISS family," says Sven Hermann, CEO ZEISS Consumer Markets. "This acquisition not only reinforces our commitment to innovation and excellence in the field of vision care and visual health but also enhances our product offerings. We are bundling our forces to tackle the global burden of myopia."

"With Brighten Optix' rich history in research and development and the strong portfolio we have built in the last 50 years, since my father founded the company, we now eagerly anticipate the new opportunities that lie ahead with ZEISS Vision Care," says Richard Wu, General Manager of Brighten Optix. "By combining our strengths, we can expand our capabilities, and drive advancements to improve and protect vision more effectively than ever before. I am immensely proud of the Brighten Optix team and excited about the journey that lies ahead of us all, becoming an integral part of ZEISS Vision Care."

As part of the acquisition, ZEISS Vision Care will continue to uphold Brighten Optix' commitment to quality and customer satisfaction. The integration of Brighten Optix into ZEISS Vision Care will begin immediately. Customers can expect to see an expanded range of products and services that combines the strengths of both companies. The immediate focus is on ensuring uninterrupted operations and customer satisfaction, fostering specialized knowledge, and enhancing the value of their offerings and services for both existing and prospective clients.

Portrait Maria Conrad
Press Contact Maria Conrad General Topics and Sustainability

ZEISS Vision Care

About ZEISS

ZEISS is an internationally leading technology company in the optics and optoelectronics industry. The ZEISS Group generated annual revenue totaling around 11 billion euros in its four segments Industrial Quality & Research, Medical Technology, Consumer Markets and Semiconductor Manufacturing Technology (updated: 30 September 2024).

For its customers, ZEISS develops, produces, and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for life sciences and materials research, as well as medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.

With a portfolio aligned with future growth areas like digitalization, healthcare and Industry 4.0 as well as a strong brand, ZEISS is shaping technological progress and, through its solutions, is extending the horizon of the world of optics and associated areas. ZEISS' significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 14% of its revenue in research and development work – ZEISS has a long tradition of high expenditure in these areas. This also represents the company's investment in the future.

With more than 46,500 employees, ZEISS operates in around 50 countries with more than 60 sales and service sites, 40 research and development sites and 35 production sites worldwide (as of 31 March 2025). The headquarters of the company, which was founded in Jena in 1846, is located in Oberkochen, Germany. The Carl Zeiss Foundation, one of Germany’s largest foundations committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.

Further information at www.zeiss.com

 

ZEISS Vision Care
ZEISS Vision Care is one of the world's leading manufacturers of eyeglass lenses and ophthalmic instruments. The unit is allocated to the Consumer Markets segment and develops and produces offerings for the entire eyeglass value chain that are distributed globally under the ZEISS brand.


Share this article